Cimeio Therapeutics, a Basel, Switzerland- and Boston, MA-based biotechnology company developing a novel approach to cell therapies, raised $50m in Series A funding.
The round was led by Versant Ventures.
Click here to read the press release
Target – Cimeio Therapeutics AG
Buyer – Versant Ventures
Seller – Shareholders